☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
prime designation
Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma
January 19, 2021
AstraZeneca's MEDI8897 Receives FDA's Breakthrough Therapy Designation (BTD) & EMA's PRIME Designation for Lower Respiratory T...
February 5, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.